NZ733366A - Purification of iduronate-2-sulfatase - Google Patents

Purification of iduronate-2-sulfatase

Info

Publication number
NZ733366A
NZ733366A NZ733366A NZ73336613A NZ733366A NZ 733366 A NZ733366 A NZ 733366A NZ 733366 A NZ733366 A NZ 733366A NZ 73336613 A NZ73336613 A NZ 73336613A NZ 733366 A NZ733366 A NZ 733366A
Authority
NZ
New Zealand
Prior art keywords
sulfatase
iduronate
purification
seq
purified recombinant
Prior art date
Application number
NZ733366A
Other languages
English (en)
Inventor
Dave Nichols
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49778401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ733366(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Priority to NZ743910A priority Critical patent/NZ743910A/en
Publication of NZ733366A publication Critical patent/NZ733366A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NZ733366A 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase NZ733366A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ743910A NZ743910A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29
NZ703093A NZ703093A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Publications (1)

Publication Number Publication Date
NZ733366A true NZ733366A (en) 2019-12-20

Family

ID=49778401

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ733366A NZ733366A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase
NZ703093A NZ703093A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase
NZ743910A NZ743910A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Family Applications After (2)

Application Number Title Priority Date Filing Date
NZ703093A NZ703093A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase
NZ743910A NZ743910A (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Country Status (39)

Country Link
US (7) US9051556B2 (enExample)
EP (2) EP3441398A1 (enExample)
JP (4) JP6171007B2 (enExample)
KR (5) KR101380740B1 (enExample)
CN (3) CN107596358A (enExample)
AR (1) AR091647A1 (enExample)
AU (3) AU2013282395C1 (enExample)
BR (1) BR112014032567B1 (enExample)
CA (2) CA2877517C (enExample)
CL (1) CL2014003567A1 (enExample)
CO (1) CO7240396A2 (enExample)
CR (1) CR20140588A (enExample)
CY (1) CY1121519T1 (enExample)
DK (1) DK2867245T3 (enExample)
DO (1) DOP2014000294A (enExample)
EA (2) EA202090044A1 (enExample)
ES (1) ES2689468T3 (enExample)
GT (1) GT201400303A (enExample)
HK (3) HK1209431A1 (enExample)
HR (1) HRP20181897T1 (enExample)
HU (1) HUE040769T2 (enExample)
IL (4) IL236315A (enExample)
LT (1) LT2867245T (enExample)
MX (3) MX393364B (enExample)
MY (3) MY180287A (enExample)
NZ (3) NZ733366A (enExample)
PE (1) PE20150720A1 (enExample)
PH (3) PH12014502871A1 (enExample)
PL (1) PL2867245T3 (enExample)
PT (1) PT2867245T (enExample)
RS (1) RS58005B1 (enExample)
SG (2) SG10201703489VA (enExample)
SI (1) SI2867245T1 (enExample)
SM (1) SMT201800612T1 (enExample)
TR (1) TR201815811T4 (enExample)
TW (2) TWI587869B (enExample)
UA (2) UA121959C2 (enExample)
WO (1) WO2014005014A2 (enExample)
ZA (2) ZA201409397B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2997976A1 (en) 2007-07-27 2016-03-23 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
WO2011044542A1 (en) 2009-10-09 2011-04-14 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
MX389073B (es) 2016-08-25 2025-03-20 Japan Chem Res Método para producir una proteína de fusión de anticuerpo.
CN106282231B (zh) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
MX2020002918A (es) 2017-10-02 2020-07-22 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas.
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
WO2020132452A1 (en) * 2018-12-20 2020-06-25 Shire Human Genetic Therapies, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
WO2020160133A1 (en) * 2019-01-30 2020-08-06 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
IL293616A (en) 2019-12-09 2022-08-01 Alexion Pharma Inc Alkaline phosphatase polypeptides and methods of using them
KR20230088811A (ko) * 2020-10-23 2023-06-20 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타제의 제조 동안 총 시알산 함량(tsac)을 제어하는 방법
MX2023009463A (es) 2021-02-12 2023-09-21 Alexion Pharma Inc Polipeptidos de fosfatasa alcalina y metodos para su uso.

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) * 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
EP0750511B1 (en) 1994-03-16 2003-06-11 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
AU4330597A (en) 1996-08-30 1998-03-19 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
WO2000050443A2 (en) 1999-02-26 2000-08-31 Millennium Pharmaceutcals, Inc. Secreted proteins and uses thereof
DE60032349T2 (de) 1999-04-26 2007-07-12 Genentech, Inc., South San Francisco Zellenzuchtverfahren für glycoproteine
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
AU7099200A (en) 1999-09-03 2001-04-10 Human Genome Sciences, Inc. 52 human secreted proteins
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
EP1255819A2 (en) 2000-02-17 2002-11-13 Incyte Genomics, Inc. Human kinases
CA2400638A1 (en) 2000-03-17 2001-09-27 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
ES2529300T3 (es) 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
WO2002098455A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
EP1501369B1 (en) 2002-04-26 2015-06-24 Genentech, Inc. Non-affinity purification of proteins
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
KR20050088136A (ko) 2002-12-23 2005-09-01 브리스톨-마이어스 스큅 컴퍼니 단백질 생산을 위한 포유류 세포 배양 방법
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
CN1759176B (zh) 2003-02-11 2012-10-03 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
JP4586027B2 (ja) 2004-01-30 2010-11-24 シャイア ファーマシューティカルズ アイルランド リミテッド 組換えアリールスルファターゼａの製造及び精製
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
JP5199073B2 (ja) 2005-06-03 2013-05-15 アレス トレーディング ソシエテ アノニム 組換えｉｌ−１８結合タンパク質の生産
CA2645739A1 (en) 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
EP3219795B1 (en) * 2008-01-18 2024-03-13 BioMarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
WO2011044542A1 (en) 2009-10-09 2011-04-14 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
JPWO2011108451A1 (ja) * 2010-03-01 2013-06-27 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
WO2011163652A2 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
ME03649B (me) 2010-06-25 2020-07-20 Shire Human Genetic Therapies Postupci i kompozicije za isporuku iduronat-2-sulfataze u cns
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
EP2623118A4 (en) 2010-09-28 2014-05-07 Kyoritsu Seiyaku Corp MUCOSAL ADJUVANT COMPOSITION
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR20130114704A (ko) 2011-01-31 2013-10-17 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 동적으로 튜닝 가능한 산란각을 갖는 산광기
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Also Published As

Publication number Publication date
EP2867245A4 (en) 2016-03-09
EA201492177A1 (ru) 2015-06-30
MX366906B (es) 2019-07-30
CA3008945A1 (en) 2014-01-03
IL261264B (en) 2021-10-31
CA2877517C (en) 2018-07-31
HRP20181897T1 (hr) 2019-01-11
US20170073652A1 (en) 2017-03-16
PH12015502408A1 (en) 2018-03-26
US20190359958A1 (en) 2019-11-28
AU2018200230B2 (en) 2020-01-02
HK1249026A1 (zh) 2018-10-26
DK2867245T3 (en) 2018-11-26
EP3441398A1 (en) 2019-02-13
JP2018121645A (ja) 2018-08-09
TW201410868A (zh) 2014-03-16
ES2689468T3 (es) 2018-11-14
US20240401010A1 (en) 2024-12-05
CA2877517A1 (en) 2014-01-03
TWI553120B (zh) 2016-10-11
KR20140002451A (ko) 2014-01-08
US20240043817A1 (en) 2024-02-08
AU2013282395A1 (en) 2015-01-29
AU2016200469A1 (en) 2016-02-18
KR101380740B1 (ko) 2014-04-11
CR20140588A (es) 2015-04-06
HK1209767A1 (en) 2016-04-08
ZA201803289B (en) 2021-04-28
CN107596357A (zh) 2018-01-19
CN107596358A (zh) 2018-01-19
WO2014005014A3 (en) 2014-02-27
US20140004096A1 (en) 2014-01-02
KR20190064542A (ko) 2019-06-10
HUE040769T2 (hu) 2019-03-28
PH12014502871B1 (en) 2015-02-23
RS58005B1 (sr) 2019-02-28
SMT201800612T1 (it) 2019-01-11
PH12015502408B1 (en) 2020-02-14
MX336715B (es) 2016-01-28
JP6171007B2 (ja) 2017-07-26
EP2867245A2 (en) 2015-05-06
TWI587869B (zh) 2017-06-21
PL2867245T3 (pl) 2019-02-28
CO7240396A2 (es) 2015-04-17
JP7594365B2 (ja) 2024-12-04
NZ743910A (en) 2019-12-20
TW201703794A (zh) 2017-02-01
DOP2014000294A (es) 2015-03-15
MX2015000190A (es) 2015-04-08
US10344270B2 (en) 2019-07-09
PH12014502871A1 (en) 2015-02-23
BR112014032567B1 (pt) 2022-09-13
GT201400303A (es) 2017-08-31
IL236315A0 (en) 2015-02-26
EA202090044A1 (ru) 2020-07-31
IL261264A (en) 2018-10-31
AU2013282395C1 (en) 2016-03-24
SI2867245T1 (sl) 2018-12-31
CN104583225A (zh) 2015-04-29
AU2013282395B2 (en) 2015-12-03
CY1121519T1 (el) 2020-05-29
SG10201703489VA (en) 2017-05-30
EP2867245B1 (en) 2018-09-12
JP2020105209A (ja) 2020-07-09
ZA201409397B (en) 2019-10-30
US20150313972A1 (en) 2015-11-05
UA129561C2 (uk) 2025-06-04
LT2867245T (lt) 2018-11-12
MX393364B (es) 2025-03-19
SG11201408761VA (en) 2015-01-29
IL287057A (en) 2021-12-01
CL2014003567A1 (es) 2015-04-24
EA034549B1 (ru) 2020-02-19
IL236315A (en) 2016-11-30
MY157087A (en) 2016-04-19
US20210317426A1 (en) 2021-10-14
KR20200143339A (ko) 2020-12-23
TR201815811T4 (tr) 2018-11-21
US12359178B2 (en) 2025-07-15
US11530393B2 (en) 2022-12-20
WO2014005014A2 (en) 2014-01-03
MY180287A (en) 2020-11-27
KR20220002227A (ko) 2022-01-06
IL248727A0 (en) 2017-01-31
JP6505629B2 (ja) 2019-04-24
KR20140004603A (ko) 2014-01-13
HK1249027A1 (zh) 2018-10-26
PT2867245T (pt) 2018-11-26
BR112014032567A2 (pt) 2017-08-01
US9051556B2 (en) 2015-06-09
AR091647A1 (es) 2015-02-18
PE20150720A1 (es) 2015-05-16
PH12020500027A1 (en) 2021-03-15
NZ703093A (en) 2017-08-25
US9492511B2 (en) 2016-11-15
MX2019008914A (es) 2019-09-26
MY192068A (en) 2022-07-25
UA121959C2 (uk) 2020-08-25
AU2018200230A1 (en) 2018-02-01
JP2016119911A (ja) 2016-07-07
JP2015523072A (ja) 2015-08-13
HK1209431A1 (en) 2016-04-01
AU2016200469B2 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
NZ733366A (en) Purification of iduronate-2-sulfatase
MY171146A (en) Compositions of glp-1 peptides and preparation thereof
MX2013013913A (es) Polipeptidos.
PH12014500923A1 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
MX2013001540A (es) Composiciones que comprende un polipeptido que tiene actividad de incremento celulolititico y un compuesto de quinona, y uso de las mismas.
UA103526C2 (ru) Воспроизведенный сурфактант, который содержит аналоги белков естественных сурфактантов sp-b и sp-c
IN2015KN00262A (enExample)
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
MY165152A (en) Cyclosporine analogue molecules modified at amino acid 1 and 3
UA109949C2 (uk) Композиція і лікарський засіб, які містять ідуронат-2-сульфатазу, і спосіб їх отримання
IN2014DN09922A (enExample)
MX2011012643A (es) 2,4-diaminopiridinas para el tratamiento de enfermedades caracterizadas por la proliferacion celular excesiva o anormal.
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MX344815B (es) Metodo para purificar el factor estimulante de colonias de granulocitos humano a partir de e. coli recombinante.
ZA201202491B (en) Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same
UA108636C2 (xx) Пептид
IN2012DN01292A (enExample)
IN2014DN09963A (enExample)
MY169650A (en) Crystalline recombinant interferon with altered spatial configuration,three-dimensional structure and uses thereof
WO2012128582A3 (en) A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
NZ601142A (en) Composition for improving brain function and method for improving brain function
WO2010119450A3 (en) An improved process for the preparation of desmopressin or its pharmaceutically acceptable salts
JO2857B1 (en) Vinyl pipers with modified activity of tumor-resistant TNF
TN2011000617A1 (en) 17 - alkyl-17 -oxy-oestratrienes
GB2517871A (en) Alternaria peptides

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2021 BY ANAQUA SERVICES

Effective date: 20200520

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2022 BY ANAQUA SERVICES

Effective date: 20210519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2023 BY ANAQUA SERVICES

Effective date: 20220523

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2024 BY ANAQUA SERVICES

Effective date: 20230524

ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20231115

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2025 BY ANAQUA SERVICES

Effective date: 20240521

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2026 BY ANAQUA SERVICES

Effective date: 20250520